GlassScriptPhysician profile
Janley D Appleton
NPI 1326047481
$1,186.24
in general payments reported to CMS, 2019-2025
22 companies · $532 in 2025
The $532 reported for 2025 was more than what 93% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.43 · 2022: $13.94 · 2023: $258 · 2024: $371 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $106.44 | 2023-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $105.90 | 2022-2023 | |
| Pfizer INC. | $104.26 | 2023-2025 | |
| Abbott Laboratories | $100.15 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Otsuka America Pharmaceutical, INC. | $92.18 | 2024-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $76.88 | 2024-2025 | |
| Dexcom, INC. | $70.22 | 2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $68.73 | 2025 | Ozempic, Rybelsus |
| Corium, LLC | $65.05 | 2024-2025 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.00 | 2021-2025 | Xifaxan |
| Scilex Pharmaceuticals INC. | $50.72 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.73 | 2023-2025 | Trintellix |
| Glaxosmithkline, LLC. | $35.15 | 2025 | Penmenvy, Bexsero, Pediarix |
| Ironshore Pharmaceuticals INC. | $35.12 | 2024 | |
| Antares Pharma, INC. | $31.66 | 2024-2025 | Xyosted |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $25.68 | 2024 | Nalu Neurostimulation System |
| Collegium Pharmaceutical, INC. | $24.41 | 2025 | Jornay Pm |
| Phadia US INC. | $23.78 | 2025 | Immunocap |
| Halozyme INC | $20.34 | 2023 | |
| Tris Pharma INC | $19.81 | 2023 | Dyanavel Xr |
| Lundbeck LLC | $19.69 | 2023 | Rexulti |
| Shield Therapeutics INC | $18.34 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janley Appleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.